Spots Global Cancer Trial Database for stage iii chronic lymphocytic leukemia
Every month we try and update this database with for stage iii chronic lymphocytic leukemia cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Bendamustine Plus Alemtuzumab for Refractory Chronic Lymphocytic Leukemia (CLL) | NCT00947388 | Recurrent Small... Refractory Chro... Stage III Chron... Stage III Small... Stage IV Chroni... Stage IV Small ... | Bendamustine Hy... Alemtuzumab | 18 Years - | Case Comprehensive Cancer Center | |
| Irradiated Donor Lymphocytes and Rituximab in Treating Patients With Relapsed or Refractory Lymphoproliferative Disease | NCT00176475 | Leukemia Lymphoma Multiple Myelom... | rituximab therapeutic all... | 18 Years - | Rutgers, The State University of New Jersey | |
| FCR or BR in Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia | NCT00769522 | Chronic Lymphoc... | Rituximab Bendamustine Cyclophosphamid... Fludarabine | 18 Years - | German CLL Study Group | |
| CD19-Specific T-cells in Treating Patients With Advanced Lymphoid Malignancies | NCT02529813 | Acute Biphenoty... Acute Lymphobla... Blasts 5 Percen... CD19 Positive Minimal Residua... Non-Hodgkin Lym... Small Lymphocyt... Stage III Chron... Stage IV Chroni... | Cyclophosphamid... Fludarabine Pho... Laboratory Biom... Tisagenlecleuce... | 1 Year - 80 Years | M.D. Anderson Cancer Center | |
| Combination Chemotherapy, Total-Body Irradiation, and Alemtuzumab in Treating Patients Undergoing an Autologous Stem Cell Transplant for Stage I, Stage II, Stage III, or Stage IV Chronic Lymphocytic Leukemia | NCT00276809 | Chronic Lymphoc... | alemtuzumab filgrastim carmustine cyclophosphamid... cytarabine dexamethasone etoposide fludarabine pho... melphalan autologous bone... peripheral bloo... radiation thera... | 18 Years - 60 Years | German CLL Study Group | |
| High-Dose Chemotherapy Followed by Total-Body Irradiation and Peripheral Stem Cell Transplantation in Treating Patients With Chronic Lymphocytic Leukemia | NCT00002788 | Leukemia | filgrastim cyclophosphamid... dexamethasone etoposide peripheral bloo... radiation thera... | 17 Years - 65 Years | Fred Hutchinson Cancer Center | |
| Lenalidomide in Treating Patients With High-Risk Chronic Lymphocytic Leukemia | NCT01271283 | Chronic Lymphoc... Stage III Chron... Stage IV Chroni... | Diagnostic Labo... Lenalidomide | 18 Years - | National Cancer Institute (NCI) | |
| Lenalidomide With or Without Rituximab in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Who Have Undergone Autologous or Syngeneic Stem Cell Transplant | NCT00833534 | Leukemia Lymphoma | rituximab lenalidomide | 18 Years - | Fred Hutchinson Cancer Center | |
| Combination Chemotherapy Followed By Alemtuzumab in Treating Patients With Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia | NCT00278213 | Prolymphocytic ... | alemtuzumab cyclophosphamid... fludarabine pho... mitoxantrone hy... | 18 Years - 70 Years | German CLL Study Group | |
| Rituximab, Cyclophosphamide, and Pegfilgrastim in Treating Patients With Leukemia or Non-Hodgkin's Lymphoma | NCT00278161 | Leukemia Lymphoma | Pegfilgrastim Rituximab Cyclophosphamid... | 18 Years - 70 Years | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Denileukin Diftitox in Treating Patients With Non-Hodgkin's Lymphoma | NCT00026429 | Leukemia Lymphoma | denileukin dift... | 18 Years - | National Cancer Institute (NCI) | |
| Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Refractory Chronic Lymphocytic Leukemia | NCT00002838 | Leukemia | Filgrastim (G-C... Cyclophosphamid... Fludarabine Pho... Peripheral Bloo... | - 65 Years | M.D. Anderson Cancer Center | |
| Obatoclax, Fludarabine, and Rituximab in Treating Patients With Previously Treated Chronic Lymphocytic Leukemia | NCT00612612 | B-cell Chronic ... Leukemia Prolymphocytic ... Refractory Chro... Stage I Chronic... Stage II Chroni... Stage III Chron... Stage IV Chroni... | obatoclax mesyl... fludarabine pho... rituximab laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| Ibrutinib in Treating Minimal Residual Disease in Patients With Chronic Lymphocytic Leukemia After Front-Line Therapy | NCT02649387 | Stage I Chronic... Stage II Chroni... Stage III Chron... Stage IV Chroni... | Ibrutinib Laboratory Biom... | 18 Years - | Mayo Clinic | |
| Phase II Trial With Correlative Laboratory Studies of Single Agent Irinotecan (Camptosar CPT-11) | NCT00005626 | Leukemia Lymphoma | Irinotecan | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Total-Body Irradiation, Tacrolimus, and Mycophenolate Mofetil Plus Bone Marrow Transplantation in Treating Patients With Hematologic Cancers | NCT00003572 | Leukemia Lymphoma Multiple Myelom... Myelodysplastic... | peripheral bloo... mycophenolate m... tacrolimus allogeneic bone... radiation thera... | 18 Years - 70 Years | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Lenalidomide With or Without Rituximab in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Who Have Undergone Autologous or Syngeneic Stem Cell Transplant | NCT00833534 | Leukemia Lymphoma | rituximab lenalidomide | 18 Years - | Fred Hutchinson Cancer Center | |
| Donor White Blood Cell Infusions and Interleukin-2 in Treating Patients Who Are Undergoing an Autologous Stem Cell Transplant for Relapsed Advanced Lymphoid Cancer | NCT00248430 | Graft Versus Ho... Leukemia Lymphoma Multiple Myelom... | aldesleukin therapeutic all... melphalan bone marrow abl... peripheral bloo... | 18 Years - 69 Years | Fred Hutchinson Cancer Center | |
| Removal of T Cells to Prevent Graft-Versus-Host Disease in Patients Undergoing Bone Marrow Transplantation | NCT00005641 | Chronic Myelopr... Graft Versus Ho... Leukemia Multiple Myelom... Myelodysplastic... | anti-thymocyte ... busulfan cyclophosphamid... cyclosporine leucovorin calc... methotrexate methylprednisol... allogeneic bone... in vitro-treate... radiation thera... | 15 Years - 60 Years | H. Lee Moffitt Cancer Center and Research Institute | |
| Bryostatin 1 Plus Cladribine in Treating Patients With Relapsed Chronic Lymphocytic Leukemia | NCT00003174 | Leukemia | bryostatin 1 cladribine | 18 Years - | Barbara Ann Karmanos Cancer Institute | |
| Vorinostat, Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | NCT00918723 | Chronic Lymphoc... Stage I Chronic... Stage I Small L... Stage II Chroni... Stage II Small ... Stage III Chron... Stage III Small... Stage IV Chroni... Stage IV Small ... | Fludarabine Pho... Cyclophosphamid... Rituximab Vorinostat | 18 Years - | Fred Hutchinson Cancer Center | |
| Chemotherapy in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia | NCT00003829 | Leukemia | cyclophosphamid... fludarabine pho... | 18 Years - | Alliance for Clinical Trials in Oncology | |
| UCN-01 in Treating Patients With Advanced Cancer | NCT00003289 | Leukemia Lymphoma Unspecified Adu... | 7-hydroxystauro... | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Donor Stem Cell Transplant in Treating Older or Frail Patients With Hematologic Cancer | NCT00296023 | Chronic Myelopr... Leukemia Lymphoma Multiple Myelom... Myelodysplastic... | anti-thymocyte ... filgrastim therapeutic all... busulfan fludarabine pho... methotrexate tacrolimus nonmyeloablativ... peripheral bloo... | 18 Years - 75 Years | University of California, San Francisco | |
| CD19-Specific T-cells in Treating Patients With Advanced Lymphoid Malignancies | NCT02529813 | Acute Biphenoty... Acute Lymphobla... Blasts 5 Percen... CD19 Positive Minimal Residua... Non-Hodgkin Lym... Small Lymphocyt... Stage III Chron... Stage IV Chroni... | Cyclophosphamid... Fludarabine Pho... Laboratory Biom... Tisagenlecleuce... | 1 Year - 80 Years | M.D. Anderson Cancer Center | |
| Epoetin Alfa in Treating Anemia in Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma and Anemia Caused By Chemotherapy | NCT00003341 | Anemia Leukemia Lymphoma Multiple Myelom... | epoetin alfa quality-of-life... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Combination Chemotherapy, Donor Stem Cell Transplant, Tacrolimus, Mycophenolate Mofetil, and Cyclophosphamide in Treating Patients With Hematologic Cancer | NCT00782379 | Leukemia Lymphoma Myelodysplastic... | busulfan cyclophosphamid... fludarabine pho... mycophenolate m... tacrolimus allogeneic hema... peripheral bloo... | 18 Years - 60 Years | Northside Hospital, Inc. | |
| Fludarabine and Rituximab With or Without Pixantrone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin Lymphoma | NCT00551239 | Leukemia Lymphoma | rituximab fludarabine pho... pixantrone dima... | 18 Years - 120 Years | CTI BioPharma | |
| Fludarabine and Rituximab With or Without Lenalidomide or Cyclophosphamide in Treating Patients With Symptomatic Chronic Lymphocytic Leukemia | NCT00602459 | Stage I Chronic... Stage II Chroni... Stage III Chron... Stage IV Chroni... | Cyclophosphamid... Fludarabine Pho... Laboratory Biom... Lenalidomide Rituximab | 18 Years - | National Cancer Institute (NCI) | |
| Donor Lymphocyte Infusion After Stem Cell Transplant in Treating Patients With Haematological Cancers | NCT01240525 | Graft Versus Ho... Leukemia Lymphoma Myeloma Myelodysplastic... | CD4 DLI No DLI | 18 Years - 69 Years | University College, London | |
| FCR or BR in Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia | NCT00769522 | Chronic Lymphoc... | Rituximab Bendamustine Cyclophosphamid... Fludarabine | 18 Years - | German CLL Study Group | |
| Cyclosporine in Treating Patients With Low Blood Counts Caused By Hematologic Cancer | NCT00031980 | Anemia Leukemia Neutropenia Thrombocytopeni... | cyclosporine | 18 Years - | Alliance for Clinical Trials in Oncology | |
| Tipifarnib in Treating Patients With Advanced Hematologic Cancer | NCT00005967 | Chronic Myelopr... Leukemia Lymphoma Multiple Myelom... Myelodysplastic... | tipifarnib | 18 Years - | National Cancer Institute (NCI) | |
| Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Refractory Chronic Lymphocytic Leukemia | NCT00002838 | Leukemia | Filgrastim (G-C... Cyclophosphamid... Fludarabine Pho... Peripheral Bloo... | - 65 Years | M.D. Anderson Cancer Center | |
| Denileukin Diftitox in Treating Patients With Non-Hodgkin's Lymphoma | NCT00026429 | Leukemia Lymphoma | denileukin dift... | 18 Years - | National Cancer Institute (NCI) | |
| Vorinostat, Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | NCT00918723 | Chronic Lymphoc... Stage I Chronic... Stage I Small L... Stage II Chroni... Stage II Small ... Stage III Chron... Stage III Small... Stage IV Chroni... Stage IV Small ... | Fludarabine Pho... Cyclophosphamid... Rituximab Vorinostat | 18 Years - | Fred Hutchinson Cancer Center | |
| Pentostatin, Cyclophosphamide, and Rituximab in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia | NCT00541034 | Leukemia Lymphoma | rituximab cyclophosphamid... pentostatin | 18 Years - 120 Years | Memorial Sloan Kettering Cancer Center | |
| Alemtuzumab-Ofatumumab in Previously Untreated Symptomatic Chronic Lymphocytic Leukemia | NCT01361711 | Stage I Chronic... Stage II Chroni... Stage III Chron... Stage IV Chroni... | alemtuzumab ofatumumab biopsy | 18 Years - | Northwestern University | |
| Chemotherapy, Radiation Therapy, Rituximab, and Umbilical Cord Blood Transplant in Treating Patients With B-Cell Non-Hodgkin's Lymphoma | NCT00387959 | Leukemia Lymphoma | filgrastim rituximab cyclophosphamid... cyclosporine fludarabine pho... mycophenolate m... allogeneic hema... umbilical cord ... total-body irra... | 18 Years - 70 Years | Memorial Sloan Kettering Cancer Center | |
| Fludarabine in Treating Patients With Chronic Lymphocytic Leukemia | NCT00049075 | Leukemia | fludarabine pho... | 16 Years - 120 Years | Canadian Cancer Trials Group | |
| Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia | NCT01886872 | Stage I Chronic... Stage II Chroni... Stage III Chron... Stage IV Chroni... | Bendamustine Hy... Ibrutinib Laboratory Biom... Quality-of-Life... Rituximab | 65 Years - | National Cancer Institute (NCI) | |
| UCN-01 in Treating Patients With Advanced Cancer | NCT00003289 | Leukemia Lymphoma Unspecified Adu... | 7-hydroxystauro... | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Cyclosporine in Treating Patients With Low Blood Counts Caused By Hematologic Cancer | NCT00031980 | Anemia Leukemia Neutropenia Thrombocytopeni... | cyclosporine | 18 Years - | Alliance for Clinical Trials in Oncology | |
| Biomarkers in DNA Samples From Patients With Chronic Lymphocytic Leukemia Previously Treated With Fludarabine-Based Therapy | NCT01145469 | Leukemia | DNA analysis gene expression... polymorphism an... laboratory biom... medical chart r... | 18 Years - 120 Years | Eastern Cooperative Oncology Group | |
| Ofatumumab, Pentostatin, and Cyclophosphamide in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | NCT01024010 | Chronic Lymphoc... Stage 0 Chronic... Stage I Chronic... Stage I Small L... Stage II Chroni... Stage II Small ... Stage III Chron... Stage III Small... Stage IV Chroni... Stage IV Small ... | Cyclophosphamid... Laboratory Biom... Ofatumumab Pentostatin | 18 Years - | Mayo Clinic | |
| Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Lymphoma or Leukemia | NCT00004084 | Leukemia Lymphoma | indium In 111 L... yttrium Y 90 ep... | 18 Years - | Garden State Cancer Center at the Center for Molecular Medicine and Immunology | |
| Combination Chemotherapy and Rituximab in Treating Patients With Chronic Lymphocytic Leukemia (CLL) That Did Not Respond to Fludarabine, CLL With Autoimmune Haemolytic Anemia (AIHA) or Richter's Transformation (RT) | NCT00309881 | Chronic Lymphoc... | rituximab cyclophosphamid... doxorubicin hyd... prednisone vincristine sul... | 18 Years - | German CLL Study Group | |
| Fludarabine With or Without Cyclophosphamide in Treating Patients With Chronic Lymphocytic Leukemia | NCT00003764 | Leukemia | cyclophosphamid... fludarabine pho... | 18 Years - 120 Years | Eastern Cooperative Oncology Group | |
| Fludarabine, Cyclophosphamide, and Rituximab in Treating Patients Who Have Chronic Lymphocytic Leukemia | NCT00003659 | Leukemia | filgrastim rituximab cyclophosphamid... fludarabine pho... | 18 Years - 75 Years | Memorial Sloan Kettering Cancer Center | |
| Biological Therapy in Treating Patients Undergoing Radiation Therapy, Chemotherapy, and Peripheral Stem Cell Transplantation for Hematologic Cancer | NCT00004061 | Leukemia Lymphoma Oral Complicati... | filgrastim palifermin cyclophosphamid... etoposide ifosfamide peripheral bloo... quality-of-life... radiation thera... | 18 Years - 65 Years | National Cancer Institute (NCI) | |
| Biological Therapy in Treating Patients Undergoing Radiation Therapy, Chemotherapy, and Peripheral Stem Cell Transplantation for Hematologic Cancer | NCT00004061 | Leukemia Lymphoma Oral Complicati... | filgrastim palifermin cyclophosphamid... etoposide ifosfamide peripheral bloo... quality-of-life... radiation thera... | 18 Years - 65 Years | National Cancer Institute (NCI) | |
| Azadirachta Indica in Treating Patients With Chronic Lymphocytic Leukemia | NCT01251250 | Refractory Chro... Stage II Chroni... Stage III Chron... Stage IV Chroni... | laboratory biom... western blottin... gene expression... pharmacological... flow cytometry fluorescence in... azadirachta ind... reverse transcr... | 18 Years - | Roswell Park Cancer Institute | |
| Pentostatin and Rituximab in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia | NCT00026351 | Leukemia Lymphoma | rituximab pentostatin | 18 Years - | National Cancer Institute (NCI) | |
| CLL-Irl Study. CTRIAL-IE (ICORG) 07-01, V7 | NCT00812669 | Leukemia | pegfilgrastim rituximab cyclophosphamid... fludarabine pho... cytogenetic ana... fluorescence in... gene expression... mutation analys... protein express... flow cytometry laboratory biom... | 0 Years - 64 Years | Cancer Trials Ireland | |
| Fludarabine and Darbepoetin Alfa in Treating Older Patients With Chronic Lymphocytic Leukemia | NCT00281892 | Chronic Lymphoc... Anemia | Fludarabine plu... Fludarabine mon... | - | German CLL Study Group | |
| Flavopiridol in Treating Patients With Chronic Lymphocytic Leukemia | NCT00003620 | B-cell Chronic ... Refractory Chro... Stage I Chronic... Stage II Chroni... Stage III Chron... Stage IV Chroni... | alvocidib laboratory biom... | 18 Years - | National Cancer Institute (NCI) | |
| FCR or BR in Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia | NCT00769522 | Chronic Lymphoc... | Rituximab Bendamustine Cyclophosphamid... Fludarabine | 18 Years - | German CLL Study Group | |
| Alemtuzumab in Treating Patients With Advanced Chronic Lymphocytic Leukemia That Did Not Respond to Previous Fludarabine | NCT00274976 | Leukemia | alemtuzumab | 18 Years - 65 Years | National Cancer Institute (NCI) | |
| Chlorambucil in Treating Patients With Advanced Chronic Lymphocytic Leukemia | NCT00017108 | Leukemia | chlorambucil cyclophosphamid... fludarabine pho... | 18 Years - 75 Years | National Cancer Institute (NCI) | |
| Combination Chemotherapy and Rituximab in Treating Patients With Chronic Lymphocytic Leukemia (CLL) That Did Not Respond to Fludarabine, CLL With Autoimmune Haemolytic Anemia (AIHA) or Richter's Transformation (RT) | NCT00309881 | Chronic Lymphoc... | rituximab cyclophosphamid... doxorubicin hyd... prednisone vincristine sul... | 18 Years - | German CLL Study Group | |
| Donor Stem Cell Transplant in Treating Patients With High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | NCT01027000 | Leukemia Lymphoma | rituximab busulfan cyclophosphamid... fludarabine pho... methotrexate sirolimus tacrolimus allogeneic stem... | 18 Years - 69 Years | Alliance for Clinical Trials in Oncology | |
| Fludarabine and Cyclophosphamide in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Chronic Lymphocytic Leukemia or Waldenstrom's Macroglobulinemia | NCT00281983 | Chronic Lymphoc... | alemtuzumab anti-thymocyte ... filgrastim rituximab therapeutic all... busulfan cyclophosphamid... cyclosporine fludarabine pho... methotrexate mycophenolate m... peripheral bloo... radiation thera... | 18 Years - 65 Years | German CLL Study Group | |
| Cyclophosphamide, Alvocidib, and Rituximab in Treating Patients With High Risk B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | NCT01076556 | Chronic Lymphoc... Prolymphocytic ... Recurrent Small... Refractory Chro... Stage I Chronic... Stage I Small L... Stage II Chroni... Stage II Small ... Stage III Chron... Stage III Small... Stage IV Chroni... Stage IV Small ... | Alvocidib Hydro... Cyclophosphamid... Diagnostic Labo... Pharmacological... Rituximab | 18 Years - | National Cancer Institute (NCI) | |
| Alemtuzumab Plus Peripheral Stem Cell Transplantation in Treating Patients With Chronic Lymphocytic Leukemia | NCT00006390 | Leukemia | alemtuzumab filgrastim cyclophosphamid... peripheral bloo... radiation thera... | 18 Years - 65 Years | Eastern Cooperative Oncology Group | |
| Fludarabine and Rituximab With or Without Pixantrone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin Lymphoma | NCT00551239 | Leukemia Lymphoma | rituximab fludarabine pho... pixantrone dima... | 18 Years - 120 Years | CTI BioPharma | |
| Combination Chemotherapy and Rituximab in Treating Patients With Chronic Lymphocytic Leukemia or Lymphocytic Lymphoma | NCT00049413 | Leukemia Lymphoma | rituximab cyclophosphamid... pentostatin | 18 Years - | Hoag Memorial Hospital Presbyterian | |
| Cyclophosphamide and Total Body Irradiation in Treating Patients Who Are Undergoing an Autologous Peripheral Stem Cell Transplant For Chronic Lymphocytic Leukemia | NCT00275015 | Chronic Lymphoc... | filgrastim carmustine cyclophosphamid... cytarabine dexamethasone etoposide fludarabine pho... melphalan bone marrow abl... peripheral bloo... radiation thera... | 18 Years - 60 Years | German CLL Study Group | |
| Alemtuzumab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia in Partial Remission or Complete Remission | NCT00458523 | Leukemia | alemtuzumab fluorescence in... mutation analys... flow cytometry | 18 Years - | National Cancer Institute (NCI) | |
| A Phase II Study of Allo-HCT for B-Cell NHL Using Zevalin, Fludarabine and Melphalan | NCT00577278 | Graft Versus Ho... Leukemia Lymphoma | rituximab fludarabine pho... melphalan sirolimus tacrolimus allogeneic hema... indium In 111 i... yttrium Y 90 ib... laboratory biom... | 18 Years - 69 Years | City of Hope Medical Center | |
| Cladribine and Rituximab as Remission Induction Therapy Followed By Rituximab and Stem Cell Mobilization in Treating Patients With CLL | NCT00072007 | Leukemia | filgrastim rituximab CHOP regimen cladribine cyclophosphamid... doxorubicin hyd... prednisone vincristine sul... | 18 Years - 65 Years | Swiss Group for Clinical Cancer Research | |
| Fludarabine, Rituximab, and Alemtuzumab in Treating Patients With Chronic Lymphocytic Leukemia | NCT00098670 | B-cell Chronic ... Stage I Chronic... Stage II Chroni... Stage III Chron... Stage IV Chroni... | alemtuzumab rituximab fludarabine pho... | 18 Years - | National Cancer Institute (NCI) | |
| Alemtuzumab Plus Peripheral Stem Cell Transplantation in Treating Patients With Chronic Lymphocytic Leukemia | NCT00006390 | Leukemia | alemtuzumab filgrastim cyclophosphamid... peripheral bloo... radiation thera... | 18 Years - 65 Years | Eastern Cooperative Oncology Group | |
| Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas | NCT02213913 | Adult Grade III... B-cell Chronic ... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Contiguous Stag... Cutaneous B-cel... Extranodal Marg... Intraocular Lym... Nodal Marginal ... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Noncontiguous S... Progressive Hai... Small Intestine... Splenic Margina... Stage 0 Chronic... Stage I Adult D... Stage I Adult D... Stage I Adult D... Stage I Adult H... Stage I Adult I... Stage I Chronic... Stage I Grade 1... Stage I Grade 2... Stage I Grade 3... Stage I Mantle ... Stage I Margina... Stage I Small L... Stage II Adult ... Stage II Chroni... Stage II Small ... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Adult... Stage III Chron... Stage III Grade... Stage III Grade... Stage III Grade... Stage III Mantl... Stage III Margi... Stage III Small... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Adult ... Stage IV Chroni... Stage IV Grade ... Stage IV Grade ... Stage IV Grade ... Stage IV Mantle... Stage IV Margin... Stage IV Small ... Testicular Lymp... Untreated Hairy... Waldenström Mac... | lenalidomide etoposide prednisone vincristine sul... doxorubicin hyd... cyclophosphamid... rituximab quality-of-life... laboratory biom... | 18 Years - | University of Chicago | |
| Dasatinib in Treating Patients With Chronic Lymphocytic Leukemia | NCT01441882 | Refractory Chro... Stage I Chronic... Stage II Chroni... Stage III Chron... Stage IV Chroni... | Dasatinib Laboratory Biom... Pharmacological... | 18 Years - | OHSU Knight Cancer Institute | |
| Chemotherapy in Treating Patients With Newly Diagnosed Chronic Lymphocytic Leukemia | NCT00004218 | Leukemia | chlorambucil cyclophosphamid... doxorubicin hyd... fludarabine pho... prednisolone vincristine sul... | - | National Cancer Institute (NCI) | |
| Rituximab, Pentostatin, Cyclophosphamide, and Lenalidomide in Treating Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | NCT00602836 | Leukemia Lymphoma | Rituximab Cyclophosphamid... Lenalidomide Pentostatin | 18 Years - 120 Years | Mayo Clinic | |
| Rituximab and GM-CSF in Treating Patients With Chronic Lymphocytic Leukemia | NCT00265915 | Leukemia | rituximab sargramostim | 15 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Fludarabine and Alemtuzumab or Cyclophosphamide Followed by Peripheral Blood Stem Cell Transplant or Alemtuzumab in Treating Patients With Advanced or Progressive Chronic Lymphocytic Leukemia | NCT00462332 | Leukemia | Fludarabine Campath Transplant Campath Fludarabine Campath Campath | - 60 Years | Gruppo Italiano Malattie EMatologiche dell'Adulto | |
| Growth Factor to Prevent Oral Mucositis in Patients With Hematologic Cancer | NCT00004132 | Drug/Agent Toxi... Leukemia Lymphoma Multiple Myelom... Oral Complicati... Radiation Toxic... | filgrastim palifermin cyclophosphamid... etoposide ifosfamide quality-of-life... radiation thera... | 12 Years - 65 Years | National Cancer Institute (NCI) | |
| Denileukin Diftitox in Treating Patients With Non-Hodgkin's Lymphoma | NCT00026429 | Leukemia Lymphoma | denileukin dift... | 18 Years - | National Cancer Institute (NCI) |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
